Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | CTSA | P10619 | 5/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125841 | 0.85 | SCN9A (0.54) | SCN9ABTKMCL1PTGDR2PARP10 | |
| SCHEMBL3128615 | 0.78 | SCN9A (0.54) | SCN9ABTKPARP10 | |
| SCHEMBL3126744 | 0.76 | SCN9A (0.59) | SCN9ABTKMCL1 | |
| SCHEMBL6922186 | 0.71 | SCN9A (0.53) | SCN9ABTKPARP10 | |
| SCHEMBL3135351 | 0.71 | PLAU (0.55) | SCN9ABTKPARP10 | |
| SCHEMBL25285978 | 0.71 | CTSA (0.56) | CTSAECE1 | |
| SCHEMBL25649417 | 0.70 | BTK (0.55) | SCN9ABTKPARP10 | |
| SCHEMBL30534933 | 0.69 | HTR5A (0.46) | CTSA | |
| SCHEMBL10989541 | 0.69 | WHR1 (0.50) | PTGDR2 | |
| SCHEMBL725893 | 0.69 | OPRM1 (0.62) | SCN9APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265866-B1 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-07-21 | — | — | EP | disclosed |
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-02-24 | — | — | US | disclosed |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. | 2004-09-30 | — | — | US | disclosed |
| EP-1265866-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | PURDUE PHARMA L.P. | 2002-04-04 | — | — | US | disclosed |
| WO-2001068612-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, CACNA1C, KYNU | SCN9A 1288/4885BTK 4872/4885CTSA 403/4885 |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | SCN9A 1388/4885BTK 4877/4885CTSA 413/4885 |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | SCN9A 1388/4885BTK 4877/4885CTSA 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.